NCT07007078 Efficacy of Dihydroartemisinin for Treating Acne Vulgaris
| NCT ID | NCT07007078 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Shanghai Zhongshan Hospital |
| Condition | Acne Vulgaris |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-06 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 60 participants in total. It began in 2025-06 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is: • Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris. Participants will: * Take DHA every day for 3 months * Visit the clinic once every month for checkups and tests
Eligibility Criteria
Inclusion Criteria: * Clinically diagnosed with acne vulgaris; * For female patients, no pregnancy plans within the next 6 months. Exclusion Criteria: * Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months; * Patients who have used topical medications for acne within the past 2 weeks; * Pregnant or breastfeeding women; * Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.
Contact & Investigator
Jingjing JIANG, MD, PhD
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT07007078 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Acne Vulgaris. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07007078 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07007078 currently recruiting?
Yes, NCT07007078 is actively recruiting participants. Contact the research team at gao.lujuan@zs-hospital.sh.cn for enrollment information.
Where is the NCT07007078 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07007078 clinical trial?
NCT07007078 is sponsored by Shanghai Zhongshan Hospital. The principal investigator is Jingjing JIANG, MD, PhD at Fudan University. The trial plans to enroll 60 participants.